Soleno Therapeutics (SLNO) Net Cash Flow (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Net Cash Flow data on file, last reported at $62.9 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 1053.77% year-over-year to $62.9 million in Q1 2026; TTM through Mar 2026 was $51.7 million, a 34.33% increase from a year earlier, with the FY2025 full-year figure at -$17.8 million, up 78.2% from the prior year.
• Net Cash Flow for Q1 2026 stood at $62.9 million, up from -$176.6 million in the prior quarter.
• Over the last five years, Net Cash Flow for SLNO reached as high as $170.2 million in Q3 2025 and fell as low as -$176.6 million in Q4 2025.
• Historically, Net Cash Flow has averaged $6.6 million across 5 years, with a median of -$4.3 million in 2022.
• Across the five-year window, Net Cash Flow surged 2377.02% in 2023 and slumped 1785.17% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at -$5.1 million in 2022, then jumped by 2377.02% to $117.2 million in 2023, then slumped by 66.3% to $39.5 million in 2024, then slumped by 546.8% to -$176.6 million in 2025, then surged by 135.64% to $62.9 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $62.9 million in Q1 2026, -$176.6 million in Q4 2025, and $170.2 million in Q3 2025.